Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

342 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J, Shimizu T, Koyama T, Iwasa S, Shimomura A, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Tamura K, Suzuki T, Takase T, Nagai R, Yamaguchi K, Semba T, Zhao ZM, Ren M, Yamamoto N. Sato J, et al. Among authors: yonemori k. Clin Cancer Res. 2022 May 2;28(9):1783-1791. doi: 10.1158/1078-0432.CCR-21-3518. Clin Cancer Res. 2022. PMID: 35180771 Free PMC article. Clinical Trial.
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J. Yonemori K, et al. Clin Cancer Res. 2005 Apr 1;11(7):2620-4. doi: 10.1158/1078-0432.CCR-04-1497. Clin Cancer Res. 2005. PMID: 15814642 Clinical Trial.
Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer.
Yonemori K, Katsumata N, Noda A, Uno H, Yunokawa M, Nakano E, Kouno T, Shimizu C, Ando M, Tamura K, Takeuchi M, Fujiwara Y. Yonemori K, et al. J Cancer Res Clin Oncol. 2008 Nov;134(11):1199-206. doi: 10.1007/s00432-008-0401-7. Epub 2008 Jun 5. J Cancer Res Clin Oncol. 2008. PMID: 18528707 Clinical Trial.
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Kouno T, Ando M, Tamura K, Katsumata N, Hasegawa T, Kinoshita T, Fujiwara Y. Yonemori K, et al. Med Oncol. 2009;26(3):344-9. doi: 10.1007/s12032-008-9127-2. Epub 2008 Nov 18. Med Oncol. 2009. PMID: 19016009
Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
Yonemori K, Ando M, Yunokawa M, Hirata T, Kouno T, Shimizu C, Tamura K, Katsumata N, Hirakawa A, Matsumoto K, Yamanaka Y, Arioka H, Fujiwara Y. Yonemori K, et al. Br J Cancer. 2009 Jan 13;100(1):50-5. doi: 10.1038/sj.bjc.6604829. Epub 2008 Dec 16. Br J Cancer. 2009. PMID: 19088717 Free PMC article. Clinical Trial.
342 results